An article in Inside Health Policy reports that eliminating the protected drug classes would not result in additional savings to the Medicare program. The article — citing a recent report by The Pew Charitable Trust on the protected classes policy — notes that while health plans would like to see more leverage over drug prices in the protected classes policy, a rollback of the policy would not save the program that much money due to factors such as strong generic drug competition and the ability of Part D plans to restrict drugs in the classes. The article also points out the widespread, bipartisan support that the six protected classes policy currently enjoys. “When CMS proposed eliminating three classes -- antidepressants, immunosuppressants and antipsychotics -- a 200-member coalition opposed the idea, as did Republicans and Democrats in both chambers. CMS subsequently backed off the proposal, then-CMS Administrator Marilyn Tavenner told Congress the agency didn’t plan to revisit it.”
The article in its entirety can be read here.
Write something about yourself. No need to be fancy, just an overview.